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INTRODUCTION 
More than 8.9 million bone fractures annually worldwide resulting in the 
occurrence of a fracture every three seconds (1). many treatments can be 
performed to manage different types of fracture, such as non-surgical 
stabilization by using wood stick wrapped around fracture limb or surgical 
bone graft for bone loss or severe trauma. Regardless of the treatment 
strategy, the ultimate goal after injury is to return the damaged tissue back to 
its original state in order to restore functionality. Unfortunately, according to 
abbreviated injury scale (AIS), the maximal level of fracture is currently 
untreatable. Today, the development of biomaterial is investigating a new way 
to handle untreatable damage.  For example, polymer application and surface 
coating technology have influenced most methods in drug delivery. In this 
research, PLGA bone coating  will be used to investigate the functionality of 
tissue proliferation. Acute inflammation is the on of the first stages of the 
body’s response to injury. Signals produced by damaged tissue relays 
information almost immediately after an injury, causing a series of wound-
healing responses including vasodilation (temporarily increasing vessel 
diameter, redness) and influx of protein-rich fluid and cells (swelling) (3) . 
Cytokines, or small signaling proteins, released from activated mononuclear 
leukocytes play an important role that affects the behavior of neighboring 
cells. (2) In this research, Inflammatory (M1) and anti-inflammatory (M2) 
macrophages were studied to understand the mechanism of cellular bone 
formation and defense at the fracture site 
 Bone healing is very complicated process involving proliferation of tissue 
cells and stem cell differentiation. A complex cascade of chemical signals and 
cells, such as growth factors, inflammatory cytokines, osteoclasts (cells that 
break down bone), and osteoblast (bone-forming cell), work as a team to 
perform a compact task. It seems like our body has a mysterious program 
that leads protein and cell present to accomplish different tasks. The injury 
site initiates inflammation and spreads a signal to recruit inflammatory 
monocytes. The inflammatory monocytes infiltrate the injury site and work to 
effectively defend and clear the virus, bacterial, and other infection from an 
external source. However, the functionality of inflammation can also lead to 
pathogenesis of inflammation and degenerative disease (2). Therefore, anti-
inflammatory monocytes patrolling in the vasculature move from the blood 
vessel to the tissue and differentiate into anti-inflammatory macrophages 
called “M2” macrophages. Anti-inflammatory macrophages clean the 
inflammation and also repair damaged tissues (3). Ideally, if we can identify 
the correlation within those components and speed up the procedure, we 
could increase the body’s regeneration rate. The previous study has shown 
the efficiency of FTY720, The US Food and Drug Administration (FDA) 
approved in 2010, promoting local vascular formation and grafted bone 
bridging. (4) Moreover, the sphingosine 1-phosphate (S1P) receptor agonist 
FTY720 therapeutically affect on lymphocytes and vascular endothelium. (5) 
Therefore, our research focuses on the combination of coating FTY720 in 
PLGA and developing strategies to increase the efficiency of recruitment of 
therapeutic cell types. 
EXPERIMENTAL DESIGN/METHODS 
 We performed a rat tibial defect to study the contribution of inflammatory 
cells to fracture repair. Three different treatments were investigated: uncoated 
allografts, PLGA-coated allografts, and PLGA-coated FTY720 drug, were 
implanted in defect created in the rat tibial bone. PLGA is an FDA-approved 
copolymer that is commonly used for in vivo drug delivery because of the 
ability to control the rate of degradation and drug . PLGA can store the drugs 
and slowly degrade to release them to the targeted tissue. FTY720 has been 
demonstrated to have the ability to promote vascular network expansion that 
supports tissue regeneration (6). Good tissue regeneration provides a better 
environment to stably grow and remodel bones (7)(8). The hypothesis is that 
the drug treated implanted bone can successfully deliver and stably release 
FTY720 to promote better bone formation in the deflect site. 8 weeks after the 
implantation surgery, the tibias from three groups were scanned by microCT 
to see the inside structure and the progress of the bone formation. MicroCT 
scanning provides detail cross-section images of rat tibial bones. The image 
showed the condition of bone fracture healing between the object’s tibial bone 
and implanted bone. Rats were divided into three groups, uncoated, PLAGA, 
and FTY. At week 8, the implanted bone was determine the condition of 
bridging to the object’s bone at each of four locations on implanted bone: 
top/left, top/right, bottom/left, and bottom/right. Moreover, the longest and 
shortest gap length from each implanted bone to the object’s bone was 
measured. Both of the longest and shortest values are zero if the bone forms 
a bridge (bone connected). One-way ANOVA was performed to analyze the 
longest and shortest length difference within three groups. The tibias were 
sectioned and placed on the slides to study its histology. CD206 and CCR7 
antibodies were used to study the inflammatory response. We would like to 
know the amount of inflammatory macrophages (M1) and anti-inflammatory 
macrophages (M2) in this stage.  Moreover, we would like to know whether 
those M1 and M2 were resident cells or came from bone marrow. Therefore, 
GFP bone marrow from the chimera rat was transplanted to our experimental 
rat, so the new form blood cells from FTP bone marrow expresses GFP after 
histology staining. The slides were also stained with antibodies, osteocalcin, 
and α-SMA to observe the distribution of bone-forming cells and blood vessel 
cells, respectively.  
 
Results  
 MicroCT scanning showed the average longest gap in uncoated group 
was 0.290mm, in PLAGA group is 0.074mm, and FTY720 group 0.091mm. 
ANOVA test showed that the gap length has significant difference in uncoated 
group with p-value 0.0002 (fig.1).  The average shortest gap in uncoated 
group is 0.097mm, in PLAGA group was 0.040mm, and FTY720 group was 
0.034mm.  ANOVA test showed that the gap length has significant difference 
in uncoated group with p-value < 0.0001 (fig.2). Uncoated group had 2 sites 
showing bone bridge formation, PLAG group had 6, and FTY720 group had 
11. Figure 1 and figure 2 have shown that the implanted bone in FTY720 
treated group actively grows toward host bone. M1 and M2 Macrophage that 
generated from chimera rat’s bone marrow were labeled by CD206+/GFP+ 
and CCR7+/GFP+, respectively. The statistic analysis show that a little more 
CCR7+/GFP+ labeled cells presented in PLGA-only group and almost the 
same amount of CCR7+/GFP+ labeled cells presented in control and FTY720 
group. The amount of CCR7+/GFP+ labeled cell has no significant difference 
within three groups. (fig.3) More CD206+/GFP+ labeled cells presented PLGA 
and FTY720 group. (fig.4) However, the amount of CD206+/GFP labeled cells 
didn't show the significant difference. To estimate how FTY720 promote 
bone-derived cells differentiate to M1 and M2 macrophage, the tibial bone 
tissue was observed under confocal microscope at week 2 to the distribution 
of CD206+/GFP+ and CCR7+/GFP+ cells. (Fig.5,6). The analysis show that 
CCR7+ cells has higher percentage that also labeled GFP+ than CD206+ 






    







Fig.1 ANOVA test Gap length 
within uncoated, PLGA, and 
FTY. ANOVA test showed the 
gap length has significant 
difference in uncoated group with 
p-value 0.0002 
Fig.2 ANOVA test Gap length 
within uncoated, PLGA, and 
FTY. ANOVA test showed that 
the gap length has significant 
difference in uncoated group with 
p-value < 0.0001 
Fig.3	  number	  of	  cells	  labeled	  with	  
CCR7	  and	  GFP,	  which	  shows	  M2	  
macrophage	  generated	  from	  bone	  
marrow.	  The amount of 
CCR7+/GFP+ labeled cell has 
no significant difference within 
three groups. 	  	  
Fig.4 number of cells labeled 
with CD206 and GFP, which 
shows M1 macrophage 
generated from bone marrow. 
the amount of CD206+/GFP+ 
labeled cells didn't show the 
significant difference 
 
Fig	  5.	  Induce	  recruitment	  of	  bone	  marrow-­‐derived	  macrophages	  (M1)	  
by	  FTY720.	  At	  week	  2,	  rat	  tibial	  bone	  sections	  were	  stained	  with	  anti-
GFP, DAPI, and CD206. The images were taken under confocal 
microscope with Scale bars = 50 µm. The dot white line represents 








       
 
Fig	  6.	  Induce	  recruitment	  of	  bone	  marrow-­‐derived	  macrophages	  (M2)	  
by	  FTY720.	  At	  week	  2,	  rat	  tibial	  bone	  sections	  were	  stained	  with	  anti-
GFP, DAPI, and CCR7. The images were taken under confocal 
microscope with Scale bars = 50 µm. The dot white line represents 
the edge of graft bone.	  
Fig.7.	  The	  analysis	  of	  the	  percentage	  of	  
CCR7+/GFP+	  and	  CD20+/GFP+	  cells	  in	  
total	  GFP+	  cell	  population.	  	  
 
DISCUSSION AND FUTURE WORK 
 The microCT showed the result that both of coated and FTY720 treated 
group form significantly more bridges from the implanted bone to the host 
bone. Furthermore, we measured the shortest and longest gap between both 
bones to see if FTY720 reduces the distance between host and donor bone. 
The average gap distance of FTY720 group was less than the PLGA coated 
group but it was not significant due to insufficient sample group size. The 
bone section slides were observed using confocal microscopy. The CD206 
(M1) and CCR7 (M2) cells were qualified in each of the slides. The ratio of M1 
and M2 containing GFP were found. However, the final analyses don’t have 
significance due to small sample size. So far, these results have 
demonstrated that FTY720 can increase bone formation through altering cell 
recruitment into the healing bone. The development of bone coating with 
FTY720 could provide better outcome in bone grafting surgery and 
investigate FTY720 functionality that better promoting defect bone healing. 
The results showed that FTY720 coated could stimulate bone formation, and 
we had successfully recruited more monocyte to the targeted site, but the fate 
of inflammatory and anti-inflammatory monocytes is still unknown. In 
conclusion, while our results are showing positive significance, further 
research will be continue on studying where monocytes came from and where 
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